profil disolusi terbanding, penetapan kadar, dan kualitas fisik tablet atorvastatin inovator, generik bernama dagang, dan generik
Clicks: 271
ID: 191310
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
271 views
43 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #19 of 31 articles by views in Cancer management and research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Atorvastatin is one of the statins which is used as the first line therapy for hyperlipidemia. The patent of atorvastatin innovator ended in 2011. Besides the innovator brand of atorvastatin, several brand and one generic atorvastatin tablet are currently marketed in Indonesia. In this research, dissolution profiles, assay and physical quality were investigated for three atorvastatin tablet samples consist of one innovator sample, two atorvastatin copy layer products (branded generic atorvastatin sample and atorvastatin generic sample). The dissolution testing were done using FDA (Food and Drug Administration) method. The result shows that the innovator and branded generic samples meet all the requirements for physical quality, meanwhile the generic sample failed to meet the disintegration test criteria. The branded generic sample has similar dissolution profile with the innovator, while the generic tablet was not similar. The assay were conducted using High Performance Liquid Chromatography (HPLC) method. The assay result of the innovator, branded generic, and generic samples respectively were 97,54%, 106,36% and 97,65% which means that all samples comply with general requirement of active pharmaceutical ingredient in tablet.
| Reference Key |
aini2015jurnalprofil
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Nurul Aini;Ratih Dian Saraswati;Intan Sari Octoberia |
| Journal | Cancer management and research |
| Year | 2015 |
| DOI |
10.22435/jki.v5i2.4403.90-97
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.